Genus Capital Management Inc. Acquires Shares of 5,390 Penumbra, Inc. $PEN

Genus Capital Management Inc. purchased a new position in shares of Penumbra, Inc. (NYSE:PEN) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 5,390 shares of the company’s stock, valued at approximately $1,383,000.

Other large investors have also bought and sold shares of the company. First Horizon Advisors Inc. grew its position in Penumbra by 404.8% during the 1st quarter. First Horizon Advisors Inc. now owns 106 shares of the company’s stock worth $28,000 after acquiring an additional 85 shares during the last quarter. AlphaQuest LLC bought a new position in shares of Penumbra in the first quarter valued at about $66,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Penumbra in the first quarter valued at about $76,000. Spire Wealth Management bought a new position in shares of Penumbra in the second quarter valued at about $91,000. Finally, Meeder Asset Management Inc. raised its holdings in shares of Penumbra by 1,966.7% in the first quarter. Meeder Asset Management Inc. now owns 372 shares of the company’s stock valued at $99,000 after buying an additional 354 shares during the last quarter. 88.88% of the stock is currently owned by institutional investors.

Insider Activity at Penumbra

In other Penumbra news, EVP Johanna Roberts sold 600 shares of the company’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $249.70, for a total transaction of $149,820.00. Following the completion of the sale, the executive vice president owned 64,257 shares in the company, valued at approximately $16,044,972.90. The trade was a 0.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Arani Bose sold 12,000 shares of the company’s stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $250.65, for a total transaction of $3,007,800.00. Following the completion of the sale, the director owned 558 shares of the company’s stock, valued at approximately $139,862.70. This represents a 95.56% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 48,430 shares of company stock worth $12,504,268. 4.20% of the stock is owned by company insiders.

Analyst Ratings Changes

PEN has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $326.00 price target on shares of Penumbra in a report on Monday, October 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Penumbra in a report on Wednesday, October 8th. Royal Bank Of Canada reduced their price objective on Penumbra from $330.00 to $325.00 and set an “outperform” rating on the stock in a report on Wednesday, July 30th. Wall Street Zen downgraded Penumbra from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Finally, BTIG Research reaffirmed a “buy” rating and set a $320.00 price objective on shares of Penumbra in a report on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $305.94.

Penumbra Stock Performance

Shares of Penumbra stock opened at $225.73 on Thursday. The firm has a fifty day moving average of $256.21 and a two-hundred day moving average of $258.61. The stock has a market capitalization of $8.80 billion, a price-to-earnings ratio of 60.03, a PEG ratio of 2.10 and a beta of 0.51. Penumbra, Inc. has a 52 week low of $221.26 and a 52 week high of $310.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.04 and a current ratio of 6.75.

Penumbra (NYSE:PEN) last issued its earnings results on Wednesday, November 5th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.90 by $0.07. The company had revenue of $354.69 million during the quarter, compared to analysts’ expectations of $340.77 million. Penumbra had a net margin of 11.54% and a return on equity of 11.55%. The business’s revenue for the quarter was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.85 EPS. Penumbra has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Penumbra, Inc. will post 3.67 EPS for the current year.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.